Spinal Cord Injury Market Analysis, Size, Share & Growth Forecast 2026–2034

Epidural Spinal Cord Stimulation Below Injury Level Enabling Voluntary Leg Movement and Standing in Chronic Complete Motor SCI Patients Who Had No Prior Voluntary Movement Has Provided the Proof-of-Concept That Lumbosacral Circuit Stimulation Can Unlock Function Below a Complete Injury.Medtronic's targeted epidural stimulation approach demonstrated voluntary lower-extremity movement in five of five complete thoracic SCI patients enrolled in a University of Louisville trial, and subsequent independent replication at Mayo Clinic, University of Minnesota, and UCSF has established epidural stimulation as reproducibly enabling voluntary movement when combined with rehabilitation. The ARCEX Therapy epidural stimulation device from Onward Medical achieved FDA Breakthrough Device designation for enabling movement in people with complete cervical SCI and is in pivotal trial development, progressing toward the first regulatory approval for a SCI-specific epidural stimulation device with functional endpoints. The mechanism involves reawakening latent sensorimotor circuits below the injury that were previously inhibited rather than destroyed by the spinal cord lesion, challenging the prior clinical assumption that complete SCI patients have no preserved circuitry below the injury level.

Riluzole INROADS North American Clinical Trials Network Phase III for Acute Cervical SCI Investigating the Sodium Channel Blocker That ALS Approval Validated as Tolerable and Mechanistically Appropriate for Reducing the Secondary Injury Sodium Influx That Follows the Initial Cord Trauma.Asterias Biotherapeutics's OPC1 oligodendrocyte precursor cell therapy demonstrated statistically significant motor improvement versus historical control in SCiStar Phase 1-2 in cervical SCI, with 4 of 6 patients showing upper extremity motor improvement meaningful enough to change functional independence level. The sub-acute injury window within 14-30 days of SCI is the target period where remyelination of preserved axons and neuroprotection through growth factor secretion from transplanted cells is hypothesised to produce the greatest recovery, and NeuroD Cell Therapy's NSC-01 neural stem cell programme from BrainStorm Cell Therapeutics targets the same sub-acute window. The absence of immunosuppression requirements for allogeneic OPC1 therapy, if confirmed in larger trials, would significantly simplify the treatment protocol compared to cell therapies in other neurological indications that require chronic immunosuppression to prevent graft rejection.

Anti-RGMa Antibody Elezanumab INROADS Phase II Signal in Acute Cervical SCI Blocking Axon Regeneration Inhibition Has Provided the First Regenerative Approach to SCI With Clinical Phase II Evidence That Supports the Phase III Investigation.Synchron's Stentrode minimally invasive blood-vessel-deployed BCI and Neuralink's N1 chip have demonstrated real-time voluntary control of computer cursors, tablet text entry, and robotic arm movement in ALS and cervical SCI patients in first-in-human trials. Synchron's stentrode implant through femoral venous access to the motor cortex region avoids open craniotomy required for electrode arrays like the Utah array used in academic BCI research, reducing surgical risk and enabling deployment outside of neurosurgical centres. BrainGate consortium's academic BCI trials have generated 20-year datasets showing signal stability, neural adaptation, and expanding command capability in paralysed patients, providing the scientific foundation that commercial BCI companies are translating into scalable implantable devices with wireless transmission and rechargeable batteries suited to long-term home use.

For related market intelligence, see the Neurology Drug Market.